N/A
N=76
National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC
Non-small Cell Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT03982459 ↗Enrolled (actual)
76
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcome: Primary: Percentage of Participants Reporting Quality of Care on Selected National Comprehensive Cancer Center (NCCN) Recommendations — 80; 0; 50; 28.6 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Decision support tool (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Francisco
- Primary completion
- Sep 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Reporting Quality of Care on Selected National Comprehensive Cancer Center (NCCN) Recommendations |
80; 0; 50; 28.6; 64.3; 91.3 | — |
| SECONDARY Median Change in Decisional Conflict Scale (DCS) Score Over Time |
20 | — |
| SECONDARY Median Scores by Item on the Satisfaction With Health Care Decision Questionnaire |
4; 4; 4; 4; 4; 4 | — |
| SECONDARY Number of Participants by Response on the Decisional Support Preference Questionnaire (DMPQ) |
5; 12; 39; 13; 2 | — |
| SECONDARY Median Total Score on the Quality of Life by the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire |
67 | — |
| SECONDARY Median Scores on the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Lung Symptom Index (NFLSI-17) |
— | — |
| SECONDARY Percentage of Participants With Reported Agreement at Post Consultation With Physician |
93.3 | — |
Summary
This study involves the evaluation of a decision support tool, based on the patient version of the NCCN guidelines, for the non-small cell lung cancer patient population.
Eligibility Criteria
Inclusion Criteria
- Over age of 18
- Able to provide informed consent
- Able to use a web-based interface
- Histologically proven or clinically apparent diagnosis of non-small cell lung cancer
- Newly diagnosed, with new primary occurrence of NSCLC, or diagnosed with a new recurrence or new progression of existing disease, and not yet treated for the new problem
- Being seen in consultation at thoracic oncology clinics
Exclusion Criteria
- Unable to fill out questionnaires
- Already treated for the current diagnosis of a new primary occurrence of NSCLC, or already treated for the new recurrence or new progression of existing disease
Data sourced from ClinicalTrials.gov (NCT03982459). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.